

For Antibiotice, 2007 was the year we made the most of existing resources and business opportunities, aspects reflected in a dramatic growth of the company's financial earnings.

Accordingly, at the end of 2007 the company turnover amounted to 229,42 million lei, reporting 17,2% increase over the similar value in 2006. The gross profit reported was 36,89 million lei, 22.6% higher as compared to the previous year, the return on investment obtained being 16,08%. Thanks to these results, Antibiotice managed to maintain its leading position in the top 10 pharmaceutical players on the Romanian market, with a market share of 3,1 %.

Against the current trend of development on the local market, highlighted by its extremely competitive nature, Antibiotice continued to diversify its product portfolio, tackling the cardio-vascular segment and the one covering dermatological affections. It has also made steps in the formulation and development of generic medicines covering antidiabetics and CNS therapeutic class. These important steps are an integrating part of the strategy for repositioning the company as a complex manufacturer of pharmaceuticals which, today, produces more than antibiotics.

In 2007 Antibiotice becomes the first Romanian pharmaceutical company to obtain the approval for its Integrated Management System (as far as the quality, the environment, the health and occupational safety are concerned). This only goes to demonstrate that today our company is manufacturing safe and efficient, high-quality drugs while protecting the environment and the health and safety of its employees.

In a nutshell, Antibiotice asserts itself as a competitive player on the pharmaceutical market and equally a top-of-mind brand amongst partners, patients and over 55.000 stockholders, all confiding in its potential for development.